IRIDEX Corporation
IRIX Healthcare Medical Devices
IRIDEX Corporation’s revenue for fiscal 2025 (year ended December 2025) was $52.7 million, up 8.23% from fiscal 2024. In the quarter to June 2026, revenue fell 7.41%, EPS fell 16.7%, free cash flow grew 130.2% and total debt rose 3.27%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow IRIX
IRIDEX Corporation (IRIX) EV/Sales
As of 16 October 2026, IRIDEX Corporation (IRIX) trades at a EV/Sales of 0.3×. Over the past ten years it has ranged from 0.2× (September 2019) to 3.4× (November 2016); the current reading is higher than 3% of that period. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.4× | (38.07%) |
| FY2024 | 0.6× | (29.28%) |
| FY2023 | 0.8× | 123.86% |
| FY2022 | 0.4× | (73.21%) |
| FY2021 | 1.4× | 92.25% |
| FY2020 | 0.7× | 44.94% |
| FY2019 | 0.5× | (42.69%) |
| FY2018 | 0.8× | (49.78%) |
| FY2017 | 1.7× | (33.43%) |
| FY2016 | 2.5× | 28.38% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.4× | 15.78% |
| Mar 2026 | 0.3× | (1.74%) |
| Dec 2025 | 0.4× | (6.39%) |
| Sep 2025 | 0.4× | 41.02% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| RBOT Vicarious Surgical Inc. compare | n/m |
| BDMD Baird Medical Investment Holdings Limited compare | n/m |
| IRIX IRIDEX Corporation | 0.3× |
| LFWD Lifeward Ltd. compare | 0.9× |
| BTCY Biotricity Inc. compare | 1.7× |
| SINT SINTX TECHNOLOGIES, INC. compare | 3.7× |
| ALUR Allurion Technologies, Inc. compare | 5.3× |
| PETV PetVivo Holdings, Inc. compare | 23.4× |
| HSCS HeartSciences Inc. compare | 556× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)